26.09.2022 - 28.09.2022Boston Marriott Burlington, One Burlington Mall Road, 01803 Burlington, Massachusetts, USA
Time: 8:30 AM - 6:00 PM
Temi della conferenza For decades, RAS has existed as an elusive therapeutic target, and drugging this high-value oncogene was deemed impossible. Despite this, the first-ever FDA-approved KRAS G12C inhibitor has demonstrated that RAS is in fact druggable and that drugging this protein unlocks a world of successful therapeutic interventions. Now, the future looks bright for treating patients with cancers harboring the RAS mutation.